On October 8, 2024, Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK, Taimei Technology), the largest digital solution provider in the pharmaceutical and medical device industry in mainland China, has successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising approximately HKD 291 million. CBI is honored to assist the professional team including sponsors and lawyers in conducting due diligence for this IPO Project.

As a leading digital solution provider in China, Taimei Technology focuses  on designing and providing industry-specific software and digital services to a variety of stakeholders in the pharmaceutical and medical device industry. Its cloud-based software products include Software as a Service (SaaS) and customized products along with related technical support. The company's core products include TrialOS, a digital collaboration platform for the research and development of pharmaceutical and medical device, and Pharma OS, a digital collaboration platform for pharmaceutical and medical device commercialization. with applications in both domestic and overseas markets.

In this IPO project, the due diligence support provided by CBI covers the background information, litigation, winding-up and bankruptcy details of the listing group, and its directors and senior management. The due diligence coverage spans over five countries and regions including mainland China, Hong Kong, the United States, France, and Singapore.